Myocardial injury related to SARS-CoV-2 mRNA vaccination: The plot thickens

European Journal of Heart FailureEarly View Invited Editorial Myocardial injury related to SARS-CoV-2 mRNA vaccination: The plot thickens Nir Levi, Nir Levi Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, IsraelSearch for more papers by this authorTal Hasin, Corresponding Author Tal Hasin [email protected] Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel Corresponding author. Jesselson Integrated Heart Center, Shaare Zedek Medical Center, 12 Shmuel Beit Street, Jerusalem 9103102, Israel. Tel: +972 50 7558415, Fax: +972 2 6555975, Email: [email protected]Search for more papers by this author Nir Levi, Nir Levi Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, IsraelSearch for more papers by this authorTal Hasin, Corresponding Author Tal Hasin [email protected] Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel Corresponding author. Jesselson Integrated Heart Center, Shaare Zedek Medical Center, 12 Shmuel Beit Street, Jerusalem 9103102, Israel. Tel: +972 50 7558415, Fax: +972 2 6555975, Email: [email protected]Search for more papers by this author First published: 29 August 2023 https://doi.org/10.1002/ejhf.3013 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.2978 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603–2615. https://doi.org/10.1056/NEJMoa2034577 2Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403–416. https://doi.org/10.1056/NEJMoa2035389 3Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021; 384: 1412–1423. https://doi.org/10.1056/NEJMoa2101765 4Larson KF, Ammirati E, Adler ED, Cooper LT, Hong KN, Saponara G, et al. Myocarditis after BNT162b2 and mRNA-1273 vaccination. Circulation 2021; 144: 506–508. https://doi.org/10.1161/CIRCULATIONAHA.121.055913 5Verma AK, Lavine KJ, Lin C-Y. Myocarditis after Covid-19 mRNA vaccination. N Engl J Med 2021; 385: 1332–1334. https://doi.org/10.1056/NEJMc2109975 6Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med 2021; 385: 2140–2149. https://doi.org/10.1056/NEJMoa2109730 7Husby A, Hansen JV, Fosbøl E, Thiesson EM, Madsen M, Thomsen RW, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: Population based cohort study. BMJ 2021; 375:e068665. https://doi.org/10.1136/bmj-2021-068665 8Buergin N, Lopez-Ayala P, Hirsiger JR, Mueller P, Median D, Glarner N, et al. Sex-specific differences in myocardial injury incidence after COVID-19 mRNA-1273 booster vaccination. Eur J Heart Fail. https://doi.org/10.1002/ejhf.2978 Published online ahead of print 20/07/23. 9Levi N, Moravsky G, Weitsman T, Amsalem I, Bar-Sheshet Itach S, Algur N, et al. A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons. Eur J Heart Fail 2023; 25: 313–318. https://doi.org/10.1002/ejhf.2687 10Mansanguan S, Charunwatthana P, Piyaphanee W, Dechkhajorn W, Poolcharoen A, Mansanguan C. Cardiovascular manifestation of the BNT162b2 mRNA COVID-19 vaccine in adolescents. Trop Med Infect Dis 2022; 7:196. https://doi.org/10.3390/tropicalmed7080196 11Dickerman BA, Gerlovin H, Madenci AL, Kurgansky KE, Ferolito BR, Figueroa Muñiz MJ, et al. Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S. veterans. N Engl J Med 2022; 386: 105–115. https://doi.org/10.1056/NEJMoa2115463 12Naveed Z, Li J, Wilton J, Spencer M, Naus M, Velásquez García HA, et al. Comparative risk of myocarditis/pericarditis following second doses of BNT162b2 and mRNA-1273 coronavirus vaccines. J Am Coll Cardiol 2022; 80: 1900–1908. https://doi.org/10.1016/j.jacc.2022.08.799 13Mueller D, Puelacher C, Honegger U, Walter JE, Badertscher P, Schaerli N, et al. Direct comparison of cardiac troponin T and I using a uniform and a sex-specific approach in the detection of functionally relevant coronary artery disease. Clin Chem 2018; 64: 1596–1606. https://doi.org/10.1373/clinchem.2018.286971 14Thurner L, Kessel C, Fadle N, Regitz E, Seidel F, Kindermann I, et al. IL-1RA antibodies in myocarditis after SARS-CoV-2 vaccination. N Engl J Med 2022; 387: 1524–1527. https://doi.org/10.1056/NEJMc2205667 15Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex. Circulation 2022; 146: 743–754. https://doi.org/10.1161/CIRCULATIONAHA.122.059970 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation